Open Access. Powered by Scholars. Published by Universities.®

Oncology Commons

Open Access. Powered by Scholars. Published by Universities.®

2,710 Full-Text Articles 10,890 Authors 351,025 Downloads 125 Institutions

All Articles in Oncology

Faceted Search

2,710 full-text articles. Page 1 of 114.

Effect Of Differences In Metabolic Activity Of Melanoma Models On Response To Lonidamine Plus Doxorubicin., Kavindra Nath, Jeffrey Roman, David S. Nelson, Lili Guo, Seung-Cheol Lee, Stepan Orlovskiy, Kevin Muriuki, Daniel F. Heitjan, Stephen Pickup, Dennis B. Leeper, Ian A. Blair, Mary E. Putt, Jerry D. Glickson 2018 University of Pennsylvania

Effect Of Differences In Metabolic Activity Of Melanoma Models On Response To Lonidamine Plus Doxorubicin., Kavindra Nath, Jeffrey Roman, David S. Nelson, Lili Guo, Seung-Cheol Lee, Stepan Orlovskiy, Kevin Muriuki, Daniel F. Heitjan, Stephen Pickup, Dennis B. Leeper, Ian A. Blair, Mary E. Putt, Jerry D. Glickson

Department of Radiation Oncology Faculty Papers

Lonidamine (LND), a metabolic modulator, sensitizes DB-1 human melanoma to doxorubicin (DOX) chemotherapy by acidifying and de-energizing the tumor. This report compares the effects of LND on two human melanoma lines, DB-1 and WM983B, which exhibit different metabolic properties. Using liquid chromatography mass spectrometry and Seahorse analysis, we show that DB-1 was more glycolytic than WM983B in vitro. 31P magnetic resonance spectroscopy (MRS) indicates that LND (100 mg/kg, i.p.) induces similar selective acidification and de-energization of WM983B xenografts in immunosuppressed mice. Over three hours, intracellular pH (pHi) of WM983B decreased from 6.91 ± 0.03 to 6 ...


Survivorship And The Skcc Cancer Support And Welcome Center, Shawnna Cannaday, RN, MSN, FNP-BC, Gregory Garber, MSW, LCSW, Rebecca Cammy, MSW, LCSW, Lisa Capparella, MSS, LCSW, OSW-C 2018 Thomas Jefferson University

Survivorship And The Skcc Cancer Support And Welcome Center, Shawnna Cannaday, Rn, Msn, Fnp-Bc, Gregory Garber, Msw, Lcsw, Rebecca Cammy, Msw, Lcsw, Lisa Capparella, Mss, Lcsw, Osw-C

Pancreatic Cancer & Related Diseases Symposium

No abstract provided.


Scientific Collaborations In Pancreatic Cancer And What's On The Horizon For Research/Clinical Trials, Jonathan R. Brody, PhD, Elda Grabocka, PhD, Michael J. Pishvaian, MD, PhD, James A. Poser, III, MD 2018 Thomas Jefferson University

Scientific Collaborations In Pancreatic Cancer And What's On The Horizon For Research/Clinical Trials, Jonathan R. Brody, Phd, Elda Grabocka, Phd, Michael J. Pishvaian, Md, Phd, James A. Poser, Iii, Md

Pancreatic Cancer & Related Diseases Symposium

No abstract provided.


Survivor Photo, TBD 2018 Thomas Jefferson University

Survivor Photo, Tbd

Pancreatic Cancer & Related Diseases Symposium

No abstract provided.


Lunch, Marianne Connolly, Bob Halinski 2018 Thomas Jefferson University

Lunch, Marianne Connolly, Bob Halinski

Pancreatic Cancer & Related Diseases Symposium

A Patient’s Story

Marianne Connolly


Pancreatic Cancer Community Impact Award

Bob Halinski, donor and community fundraiser


Questions And Answers, TBD 2018 Thomas Jefferson University

Questions And Answers, Tbd

Pancreatic Cancer & Related Diseases Symposium

No abstract provided.


What To Expect From Your Oncology Care Team, Eleanor Vanderklok, CRNP, AOCNP 2018 Thomas Jefferson University

What To Expect From Your Oncology Care Team, Eleanor Vanderklok, Crnp, Aocnp

Pancreatic Cancer & Related Diseases Symposium

No abstract provided.


Advances In Genetic Testing For Pancreatic Cancer, Veda N. Giri, MD 2018 Thomas Jefferson University

Advances In Genetic Testing For Pancreatic Cancer, Veda N. Giri, Md

Pancreatic Cancer & Related Diseases Symposium

No abstract provided.


Precious Data: 2018 Interim Report From The Jefferson Pancreas Tumor Registry, Theresa Yeo, PhD, MPH, MSN, AOCNP 2018 Thomas Jefferson University

Precious Data: 2018 Interim Report From The Jefferson Pancreas Tumor Registry, Theresa Yeo, Phd, Mph, Msn, Aocnp

Pancreatic Cancer & Related Diseases Symposium

No abstract provided.


Update On Multimodal Therapy For Pancreatic Cancer, Harish Lavu, MD 2018 Thomas Jefferson University

Update On Multimodal Therapy For Pancreatic Cancer, Harish Lavu, Md

Pancreatic Cancer & Related Diseases Symposium

No abstract provided.


Anti-Aging Therapy: Can We Age Cancer Cells So They Stop Growing?, Jonathan R. Brody, PhD 2018 Thomas Jefferson University

Anti-Aging Therapy: Can We Age Cancer Cells So They Stop Growing?, Jonathan R. Brody, Phd

Pancreatic Cancer & Related Diseases Symposium

No abstract provided.


An Update On Personalized Therapy For Pancreatic Cancer, Michael J. Pishvaian, MD, PhD 2018 Georgetown Lombardi Comprehensive Cancer Center

An Update On Personalized Therapy For Pancreatic Cancer, Michael J. Pishvaian, Md, Phd

Pancreatic Cancer & Related Diseases Symposium

No abstract provided.


Welcome And Program Overview, Charles J. Yeo, MD 2018 Thomas Jefferson University

Welcome And Program Overview, Charles J. Yeo, Md

Pancreatic Cancer & Related Diseases Symposium

No abstract provided.


Breakfast With The Experts, TBD 2018 Thomas Jefferson University

Breakfast With The Experts, Tbd

Pancreatic Cancer & Related Diseases Symposium

Continental Breakfast, Informational Tables & Scientific Poster Presentations


Proteomic Profiling Of Serum Derived Exosomes From Prostate Cancer Patients, David Turay 2018 Selected Works

Proteomic Profiling Of Serum Derived Exosomes From Prostate Cancer Patients, David Turay

David Turay, MD

Touted among the major achievements in the diagnosis and management of Prostate cancer (PCa) in the past few decades has been, the dramatic decline of men with advanced/metastatic PCa at diagnosis coupled with a significant improvement ( >90%) in the five and ten year survival rates of the disease. Non-palpable PCa (potentially clinically treatable disease) now accounts for 70-80% of all newly diagnosed cases of PCa. Preceding these changes by about a decade was the introduction of Prostatic Specific Antigen (PSA) into clinical practice; first as biomarker for monitoring response to therapy and subsequently as a complementary screening tool. It ...


Tumor Biology And Racial Disparities In Reconstruction After Mastectomy: A Seer Database Analysis, Sarah J. Ullrich, Michael C. Smith, Paul J. Chung, Sara Y. Kim, Gainosuke Sugiyama 2018 Yale University School of Medicine

Tumor Biology And Racial Disparities In Reconstruction After Mastectomy: A Seer Database Analysis, Sarah J. Ullrich, Michael C. Smith, Paul J. Chung, Sara Y. Kim, Gainosuke Sugiyama

Journal of Health Disparities Research and Practice

Introduction:

Significant disparities in immediate breast reconstruction after mastectomy have persisted, and may even be increasing, despite large-scale efforts to minimize them, such as the Women’s Health and Cancer Rights Act of 1998. Immediate breast reconstruction has been shown to lead to higher rates of surgical satisfaction, minimize delay in post-operative cancer treatment, and improve the quality of life and overall well-being of mastectomy patients. However only 25-40% of eligible women in the United States receive reconstruction. The rate of reconstruction is even lower in African American and Hispanic women compared to White women. To better understand this disparity ...


Functional Radical Cervical Dissection For Differentiated Thyroid Cancer: The Experience Of A Single Center, Tulin Adrian, Lucian Alecu, Catalina Poiana, Luminita Tomescu, Iulian Slavu, Raluca Tulin, Silviu Pituru, Cristina Orlov, Radu Jecan, Balalau Cristian, Anca Pantea Stoian, Razvan Hainarosie, Cornelia Nitipir 2018 Prof. Dr. Agrippa Ionescu Emergency Hospital, Department of General Surgery, Bucharest, Romania

Functional Radical Cervical Dissection For Differentiated Thyroid Cancer: The Experience Of A Single Center, Tulin Adrian, Lucian Alecu, Catalina Poiana, Luminita Tomescu, Iulian Slavu, Raluca Tulin, Silviu Pituru, Cristina Orlov, Radu Jecan, Balalau Cristian, Anca Pantea Stoian, Razvan Hainarosie, Cornelia Nitipir

Journal of Mind and Medical Sciences

There is ongoing debate regarding the role of neck dissection in differentiated thyroid cancer, about its usefulness in elective settings, and the increased costs regarding morbidity and operative time. This retrospective study aimed to determine the rate of metastases in cervical lymph nodes, to examine the morbidity of this surgery, and to assess whether a pattern of distribution of tumor cells concerning neck lymphatic compartments exists. The most frequent type of cancer to metastasize was papillary cancer, the majority of patients were young with a median of 30 years, predominantly females. Differentiated thyroid cancer frequently metastasizes to the central and ...


Can Non-Small Cell Lung Cancer Histologic Subtypes Predict Survival? A Single Institution Experience, Cornelia Nitipir, Cristina Orlov, Ana-Maria Popa, Mihaela Olaru, Iulian Slavu, Iaciu Cristian, Razvan Hainarosie, Anca Pantea Stoian, Balalau Cristian 2018 Carol Davila University of Medicine and Pharmacy, Elias University Emergency Hospital, Department of Oncology, Bucharest, Romania

Can Non-Small Cell Lung Cancer Histologic Subtypes Predict Survival? A Single Institution Experience, Cornelia Nitipir, Cristina Orlov, Ana-Maria Popa, Mihaela Olaru, Iulian Slavu, Iaciu Cristian, Razvan Hainarosie, Anca Pantea Stoian, Balalau Cristian

Journal of Mind and Medical Sciences

Introduction. The latest histological classification of lung adenocarcinoma includes lepidic, acinar, papillary, micropapillary, and solid as subtypes. Testing these subtypes for their prognostic and predictive value is an ongoing scientific challenge. The present research article aims to describe the influence this classification has on patient survival.

Materials and Methods. Thirty-three patients were included in the trial. The most important enrollment criterion was the clear specification of the adenocarcinoma subtype in the pathology report. Patients were stratified into three groups which included the adenocarcinoma pathological subtypes as follows: lepidic (LEP), acinar and papillary (ACN/PAP), and micropapillary/solid (MIP/SOL). The ...


Sentinel Lymph Node In Early Stage Ovarian Cancer; A Literature Review, Irina Balescu, Nicolae Bacalbasa, Mihaela Vilcu, Vladislav Brasoveanu, Iulian Brezean 2018 Ponderas Academic Hospital, Department of Visceral Surgery, Bucharest, Romania

Sentinel Lymph Node In Early Stage Ovarian Cancer; A Literature Review, Irina Balescu, Nicolae Bacalbasa, Mihaela Vilcu, Vladislav Brasoveanu, Iulian Brezean

Journal of Mind and Medical Sciences

Although sentinel lymph node mapping has been widely implemented in gynecological malignancies in order to minimize the number of unnecessary lymph node dissections and to diminish postoperative morbidity rate, little is known about ovarian cancer sentinel lymph node mapping. This article presents a literature review regarding the effectiveness, safety and benefits of this method.

Sentinel lymph node detection in early stage ovarian cancer seems to be a safe and effective method, able to minimize the rate of patients submitted to unnecessary lymph node dissection. The second goal of the procedure, to minimize the risk of missing involved lymph nodes, seems ...


Biological Therapy In The Treatment Of Melanoma, Simona Roxana Georgescu, Mihaela Roxana Ioghen, Maria Isabela Sarbu, Alexandra-Florentina Ion, Ela Ghita, Cristina-Iulia Mitran, Madalina-Irina Mitran, Vasile Benea, Mircea Tampa 2018 Carol Davila University of Medicine and Pharmacy, Department of Dermatology and Venereology, Bucharest, Romania

Biological Therapy In The Treatment Of Melanoma, Simona Roxana Georgescu, Mihaela Roxana Ioghen, Maria Isabela Sarbu, Alexandra-Florentina Ion, Ela Ghita, Cristina-Iulia Mitran, Madalina-Irina Mitran, Vasile Benea, Mircea Tampa

Journal of Mind and Medical Sciences

Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable results. This therapy is based on stimulation of the immune system to fight tumoral cells through: injection of cytokines with immunomodulatory properties (interleukin-2, alpha-interferon), vaccination with tumor antigens or immune cells that process tumor antigens, adoptive immunotherapy, inhibition of immune checkpoints (PD-1, CTLA-4), inhibition or stimulation of immune modulator molecules (OX-40, LAG-3), inhibition of signaling pathways ...


Digital Commons powered by bepress